Eating disorders (EDs) represent a major area of concern under GLP-1 treatment. Tirzepatide profoundly alters the relationship with food, which can improve some EDs but also reveal or worsen others.
EDs and Obesity: A Frequent Comorbidity
Binge eating disorder affects 20 to 30% of patients with obesity, compared to 2 to 3% in the general population. It is characterized by episodes of excessive food intake with loss of control, without compensatory behaviors (unlike bulimia). It is the most common ED among patients eligible for GLP-1 treatments.
Night eating syndrome affects 10 to 15% of patients with obesity: more than 25% of daily caloric intake is consumed after dinner. Cognitive restriction (excessive control over eating alternating with ‘cravings’ or ‘breakdowns’) is also very common.
Effects of Tirzepatide on EDs
Tirzepatide can improve binge eating disorder by reducing compulsive cravings and ‘food noise’ (mental food chatter). A study published in the International Journal of Eating Disorders (2024) shows a 60% reduction in binge eating episodes in patients on GLP-1 agonists after 6 months of treatment.
However, tirzepatide can also present challenges. Severe caloric restriction due to reduced appetite can lead to orthorexia (an obsession with healthy eating) or restrictive anorexia. The fear of weight regain can fuel excessive control behaviors. Dietary ‘rebound’ upon treatment discontinuation is a major risk for ED relapse.
Warning Signs to Recognize
- Voluntarily and repeatedly eating less than 800 kcal/day
- Obsessively weighing food with anxiety if unable to do so
- Systematically avoiding social eating situations
- Inducing vomiting or taking laxatives after an ‘excess’
- Compulsive exercise to ‘compensate’ for a meal
- Extreme guilt after eating normally
- Food-related thoughts occupying more than 3 hours per day
Contraindications and Precautions
Tirzepatide is formally contraindicated in cases of active anorexia nervosa (BMI < 17.5) or bulimia with regular vomiting. For patients with a history of EDs in remission, treatment is possible but requires reinforced psychological follow-up (minimum monthly).
Systematic screening for EDs is recommended before initiating tirzepatide. The SCOFF questionnaire (5 simple questions) and the BES (Binge Eating Scale) are validated tools usable in consultation. Any positive score warrants a specialized evaluation.
Integrated Management
Ideal management combines an endocrinologist/nutritionist (for tirzepatide and diet), a psychologist/psychiatrist specializing in EDs (for therapeutic work), and a dietitian trained in EDs (for dietary rehabilitation without restriction). Cognitive-behavioral therapy (CBT) is the gold standard treatment for EDs, with a high level of evidence.
Track your progress with the MounjaGO app.
FAQ
Does Tirzepatide help with binge eating disorder?
Yes, studies show a 60% reduction in binge eating episodes with GLP-1. Tirzepatide reduces compulsive cravings and ‘food noise.’ However, psychological follow-up remains essential to address underlying causes.
Can Mounjaro cause an eating disorder?
Tirzepatide does not cause EDs, but it can reveal a tendency towards excessive restriction or orthorexia in vulnerable patients. Eating less than 800 kcal/day or weighing food with anxiety are warning signs.
Can Mounjaro be taken with a history of bulimia?
Tirzepatide is contraindicated in cases of active bulimia with vomiting. If bulimia is in remission, treatment is possible with monthly psychological follow-up. Discuss this with your psychiatrist and endocrinologist.